Moderna (MRNA) spent four years as Wall Street’s most hated biotech — the stock shed 94% between 2021 and 2025 as Covid vaccine demand dried up and mRNA technology became politically radioactive. But something has quietly shifted. In June, FDA advisors unanimously backed Moderna’s mRNA flu vaccine, capping a 20% stock rally. At the same time, institutional buying flows in Moderna have moved from “C-grade” to “B-grade” in quantitative tracking models that monitor smart money movement. The political headwinds that crushed the stock may be reversing as Washington, facing pressure from China’s dominance in drug development, rediscovers the value of America’s mRNA biotechnology edge.
The fundamental story is compelling. At Moderna’s annual Science Day on June 25, the company outlined an accelerating oncology pipeline centered on what it calls “cancer vaccines” — programmable mRNA therapies that can be tailored to individual patients or deployed as off-the-shelf treatments targeting common cancer markers. The lead drug, intismeran autogene, is in Phase 3 trials for melanoma (skin cancer), with results expected by year-end 2026. Analysts at Morningstar project the therapy could generate over $3.5 billion in annual revenue by 2035. Beyond melanoma, the same platform is being tested for kidney and lung cancers. Additionally, Moderna is developing “multiplex” therapies designed to attack multiple cancer targets simultaneously — potentially the next leap in oncology effectiveness. Meanwhile, RFK Jr., once the company’s nemesis, has acknowledged publicly that the U.S. is losing its biomedical edge to China, and the FDA’s Operation TrialBlazer program is fast-tracking clinical research timelines — a direct tailwind for Moderna’s pipeline.
For retail investors, Moderna represents an asymmetric setup. The stock is still deeply discounted from its 2021 highs due to political and sentiment overhang — not because of a fundamental collapse in the underlying technology. The mRNA platform is proven (the Covid vaccine went from concept to approval in 10 months), and it’s now being pointed at cancer, influenza, RSV, and other large markets. The FDA flu vaccine approval removes a key near-term risk, and the Phase 3 melanoma data due by year-end 2026 is a potential catalyst. Investors willing to take a 12–24 month view on a volatile biotech should watch Moderna’s oncology data closely — the next chapter for this company could look very different from the last four years.
